Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.
The experimental drug ABT-981 fails to show significant improvements in pain and joint symptoms compared with placebo in patients with hand osteoarthritis (OA), according to a phase IIa trial presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held in Madrid, Spain.
Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
AMG-557, an inducible T-cell costimulator (ICOS) ligand inhibitor, showed efficacy and safety in a randomized multicentre trial that included patients with lupus arthritis from eight centres in the US, France, Malaysia and Germany.
Feelings of injustice and low socioeconomic status can have a significant impact on disease severity in patients with fibromyalgia, according to data from a large survey presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.
The fully-human immunocytokine dekavil (also known as F8-IL10) has demonstrated signs of safety and efficacy in patients with active rheumatoid arthritis (RA) in a phase I study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017.
Vobarilizumab, a nanobody consisting of an anti-interleukin 6 (IL-6) receptor domain developed for the treatment of rheumatoid arthritis (RA), is shown to be safe and efficacious in RA patients with inadequate response to methotrexate in a study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.